Exploration of the function of the AT2 receptor, as well as investigation of the medical potential of AT2 agonistic molecule entities have both been an important target of academic research for the past 10-15 years.
The AT2 receptor is expressed and activated in the fetus where it supports organ development and differention, and in damaged adult tissue where it restitutes morphology and function, restores heart function after myocardial infarction, reduces inflammation, regenerates neural tissue - to mention but a few of the beneficial effects.
Chronic inflammation is a key pathological expression in many disease areas which require pharmacological treatment for long periods of time, e.g. neurological diseases, skin diseases and diseases of the central internal organs. C21 has in preclinical research demonstrated potent anti-inflammatory capabilities for a number of these disease areas.